| Citations |
- Iida Y et al. Contrasting effects of cyclophosphamide on anti-CTL-associated protein 4 blockade therapy in two mouse tumor models. Cancer Sci. 108, 1974-1984 (2017)(PMID:28787548)
- Selby MJ et al. Preclinical Development of Ipilimumab and Nivolumab Combination Immunotherapy: Mouse Tumor Models, In Vitro Functional Studies, and Cynomolgus Macaque Toxicology. PLoS One. 11, e0161779 (2016)(PMID:27610613)
- Sivick KE et al. Magnitude of Therapeutic STING Activation Determines CD8+ T Cell-Mediated Anti-tumor Immunity. Cell Rep. 25, 3074-3085.e5 (2018)
(PMID:30540940)
- Wang B et al. Combination cancer immunotherapy targeting PD-1 and GITR can rescue CD8+ T cell dysfunction and maintain memory phenotype. Sci Immunol. 3, eaat7061 (2018)(PMID:30389797)
- Freeman ZT et al. A conserved intratumoral regulatory T cell signature identifies 4-1BB as a pan-cancer target. J Clin Invest. 130, 1405-1416 (2020)(PMID:32015231)
- Vormehr M et al. Dexamethasone premedication suppresses vaccine-induced immune responses against cancer. ONCOIMMUNOLOGY, 9, e1758004 (2020)
|